Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 26 Oct 2022 Results assessing the Association between fentanyl use and virologic suppression in an HIV-infected cohort of people who use/inject drugs presented at the 16th International Congress on Drug Therapy and HIV Infection
- 23 Oct 2019 New trial record